How tumour necrosis factor blockers interfere with tuberculosis immunity.
about
IMMUNOLOGY OF TUBERCULOSISCellular and Molecular Connections between Autophagy and InflammationNew insights into the impact of neuro-inflammation in rheumatoid arthritisInflammatory Bowel Disease Drugs: A Focus on AutophagyPhosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathologyPhosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected miceSuccessful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse modelIdentification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growthNovel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosisImmune subversion by Mycobacterium tuberculosis through CCR5 mediated signaling: involvement of IL-10Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasisDiametric Role of the Latency-Associated Protein Acr1 of Mycobacterium tuberculosis in Modulating the Functionality of Pre- and Post-maturational Stages of Dendritic Cells.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsReactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice.Latent tuberculosis infection: myths, models, and molecular mechanismsIncreased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens.Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation.M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model.Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infectionCytokine and lipid mediator networks in tuberculosisThe human condition: an immunological perspective.Immunomodulation by vitamin D: implications for TB.The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with Mycobacterium tuberculosis.Molecular and biochemical characterization of recombinant guinea pig tumor necrosis factor-alphaNovel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety ConsiderationsThe transcription factor NFATp plays a key role in susceptibility to TB in mice.Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosisQuantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonistsPPD-induced monocyte mitochondrial damage is associated with a protective effect to develop tuberculosis in BCG vaccinated individuals: A cohort study.Autophagy and IL-1 Family Cytokines.Coexistent Malnutrition Is Associated with Perturbations in Systemic and Antigen-Specific Cytokine Responses in Latent Tuberculosis Infection.Macrophages in tuberculosis: friend or foe.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Clinical trials for authorized biosimilars in the European Union: a systematic review.Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralization.Clinical Evaluation of Humira® Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics.Targeting Innate-Like T Cells in Tuberculosis.Diabetes and Tuberculosis.Mycobacterial Dormancy Systems and Host Responses in Tuberculosis.
P2860
Q22241115-7FD455B0-1228-49EE-9628-215B5DEA5CEEQ26798207-7FD16C1A-67CA-442E-AFBE-51FAC63962D0Q27023946-40EDB362-B6B9-4D18-A6C8-B1B8E75CA5D9Q28066443-15131906-58AF-43A9-AE7F-DF6EB7FF2597Q28389823-185E0E02-7FFE-4322-AA71-B0D6B25F2FB4Q28477281-9ED02B3C-16D8-47BC-B554-B399C1179CF9Q28480511-76E9FF69-FC55-457B-9D84-C095F4A973B4Q28539975-A8B9CBCD-1BC5-4E43-B83D-81BBBD2E8B5CQ28830471-0A58371D-419B-4CC7-A8F6-D8BFFAAFE6D5Q31155201-494BA8F3-48FD-46CA-B47B-88BF1FBD8C49Q33571752-4EB9C2CA-1333-4AC0-B959-B2677CED71BFQ33736485-6ED9C4E5-12A0-475F-A294-4B2D42749E75Q33809045-6D0138B2-69F1-44C9-B9E6-8CAB6CE29A33Q34087566-41512827-6E93-41E6-9BB2-9F8A474D1FD2Q34297816-55F10183-F864-4D3F-8A9D-00293E1E1386Q34484151-3532319C-39D4-4C8F-9ED7-FD045E5E3169Q34501038-A296A176-8B68-45E8-863A-BC36B1E391F4Q34684708-EDA1F511-0AF4-409E-BF4A-16DF8D06DE09Q35022769-26942A65-DE0D-426F-B0A5-7CFF01AFAE31Q35111389-AA20CBC2-23C9-487E-ADE8-0DC272A5B23CQ35117086-E421D3CB-96A2-4880-B038-2E7B5610F45BQ35188878-D8728BB8-DE3B-407E-BC44-5157DD22F401Q35447373-39DD8F04-86A1-4919-9108-66C0B5C842D3Q35558240-B66D4965-8DDC-48B3-85EE-E2545378CC1BQ35592437-A47A3C5C-6832-4321-AA24-AA0955B6FF37Q35826779-16B166CB-67B1-4A52-8149-91E43CF015A2Q36109541-D4E533D0-C2C9-499B-BE8D-D91A0C266270Q36169358-29515BF2-54A1-4685-B10C-4FDEF0B5D780Q36246140-51F83C3A-3E7B-419C-A411-689576590967Q36286190-724F0F8C-DA7F-4A1B-A1BB-5FDE0C8E2708Q36742485-4A37B682-2E6C-4996-8EA0-D4472ED83AE3Q36764368-346A69E9-D6E0-4CFE-87C6-CD346CB4B124Q37147624-34F54A4A-93DB-4B88-9320-403B1E688393Q37358271-18FF85F8-EC02-45D9-B9A2-2BE749EBF0E4Q37399588-160E99B0-2E8D-4CE5-B9F2-52A6EF5F68E1Q37420149-CB564AEF-8173-4B9B-B895-0F64E64FA9E4Q37443755-E87CFFD4-80D6-4E51-A2F0-055D077F6675Q37522519-4C067CE1-AC1C-4CE5-A2DF-A5E98C6E7794Q37590128-9FD5E514-FC52-4B81-A0DE-8F2126B53CDFQ37642050-75B62A94-12EA-44F7-BE25-496263B169A5
P2860
How tumour necrosis factor blockers interfere with tuberculosis immunity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
How tumour necrosis factor blockers interfere with tuberculosis immunity.
@en
How tumour necrosis factor blockers interfere with tuberculosis immunity.
@nl
type
label
How tumour necrosis factor blockers interfere with tuberculosis immunity.
@en
How tumour necrosis factor blockers interfere with tuberculosis immunity.
@nl
prefLabel
How tumour necrosis factor blockers interfere with tuberculosis immunity.
@en
How tumour necrosis factor blockers interfere with tuberculosis immunity.
@nl
P2860
P1476
How tumour necrosis factor blockers interfere with tuberculosis immunity
@en
P2093
P2860
P356
10.1111/J.1365-2249.2010.04146.X
P577
2010-05-18T00:00:00Z